Publications dans lesquelles il/elle collabore avec Jorge Manzanares Robles (25)

2017

  1. Disruption of blood–brain barrier integrity in postmortem alcoholic brain: preclinical evidence of TLR4 involvement from a binge-like drinking model

    Addiction Biology, Vol. 22, Núm. 4, pp. 1103-1116

2014

  1. Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice

    British Journal of Pharmacology, Vol. 171, Núm. 11, pp. 2814-2826

2012

  1. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection

    Stroke, Vol. 43, Núm. 1, pp. 211-219

  2. Chronic blockade of cannabinoid CB 2 receptors induces anxiolytic-like actions associated with alterations in GABA A receptors

    British Journal of Pharmacology, Vol. 165, Núm. 4, pp. 951-964

  3. Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation

    American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 302, Núm. 5

2011

  1. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors

    Neurobiology of Aging, Vol. 32, Núm. 4, pp. 631-645

  2. Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation

    Neuropsychopharmacology, Vol. 36, Núm. 4, pp. 805-818

2005

  1. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors

    European Journal of Pharmacology, Vol. 511, Núm. 1, pp. 9-19

  2. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT1AR agonists with selectivity over α1- adrenoceptors

    Journal of Medicinal Chemistry, Vol. 48, Núm. 7, pp. 2548-2558

2003

  1. Design and synthesis of S-(-)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2- a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist

    Bioorganic and Medicinal Chemistry Letters, Vol. 13, Núm. 8, pp. 1429-1432

2002

  1. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

    Synapse, Vol. 44, Núm. 1, pp. 23-35

  2. Cerebrospinal fluid and plasma concentrations of nitric oxide metabolites are increased in dementia with Lewy bodies

    Neuroscience Letters, Vol. 333, Núm. 2, pp. 151-153

  3. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Δ9-tetrahydrocannabinol

    Neurotoxicity Research, Vol. 4, Núm. 3, pp. 211-218

2001

  1. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration

    Journal of Neurochemistry, Vol. 78, Núm. 6, pp. 1415-1427

  2. Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT1A receptor agonist

    Pharmacology, Vol. 62, Núm. 4, pp. 234-242

2000

  1. Prenatal Δ9-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: Sex-dependent differences

    Developmental Brain Research, Vol. 120, Núm. 1, pp. 77-81

  2. Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland

    Biochemical and Biophysical Research Communications, Vol. 270, Núm. 1, pp. 260-266

  3. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen

    Life Sciences, Vol. 66, Núm. 6, pp. 485-494

1999

  1. Identification of endocannabinoids and cannabinoid CB1 receptor mRNA in the pituitary gland

    Neuroendocrinology, Vol. 70, Núm. 2, pp. 137-145

  2. Pharmacological and biochemical interactions between opioids and cannabinoids

    Trends in Pharmacological Sciences, Vol. 20, Núm. 7, pp. 287-294